Current Opinion in Supportive and Palliative Care最新文献_第2页

Patient and carer experiences of cancer cachexia and its management. 癌症恶病质患者和护理者的经历及其管理。

IF 1.9 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI: 10.1097/SPC.0000000000000710

Megan Bowers, Irene J Higginson, Matthew Maddocks

{"title":"Patient and carer experiences of cancer cachexia and its management.","authors":"Megan Bowers, Irene J Higginson, Matthew Maddocks","doi":"10.1097/SPC.0000000000000710","DOIUrl":"10.1097/SPC.0000000000000710","url":null,"abstract":"Purpose of review: To explore the contributions of recent qualitative literature in progressing understanding of the experiences of cancer cachexia, and its management, from the perspectives of patients and unpaid/family carers.Recent findings: Challenges with conducting everyday activities, maintaining independence, and continuing usual roles within the family are sources of distress. Patients and carers value individualization, flexibility, and carer involvement in physical activity/exercise interventions. In psychosocial/educational interventions that were positively perceived, the opportunity to talk about cachexia was appreciated, leading to improved health literacy, awareness about nutrition, and relationships with food. However, the general patient and carer experience around clinical acknowledgement and management of cachexia remains poor.Summary: Eating-related distress and conflicts, lack of understanding about cachexia, and the visibility of weight loss remain recurring themes amongst literature on experiences of cancer cachexia. Studies exploring preferences for, and experiences of, interventions have primarily focused on physical activity or exercise. Psychosocial/educational and physical activity/exercise interventions are valued and perceived to alleviate some of the key quality of life issues amongst patients with cancer cachexia and their unpaid/family carers.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141564883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A traffic light approach for treatment and supportive care stratification in lung cancer. 肺癌治疗和支持护理分层的交通灯方法。

IF 1.9 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1097/SPC.0000000000000716

Iain Phillips, Lise Nottelmann, Mark Stares

{"title":"A traffic light approach for treatment and supportive care stratification in lung cancer.","authors":"Iain Phillips, Lise Nottelmann, Mark Stares","doi":"10.1097/SPC.0000000000000716","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000716","url":null,"abstract":"Purpose of review: Comprehensive supportive care interventions for patients with lung cancer are being investigated in a range of ways, including: early palliative care, prehabilitation and rehabilitation. We review recent literature on supportive care and propose a traffic light system to individualise comprehensive supportive care. Green for those very likely to receive anti-cancer treatment, red for those very unlikely to receive anti-cancer treatment and orange where the chance of accessing treatment is uncertain. Comprehensive supportive care can be individualised based on the group a particular patient is in.Recent findings: Lung cancer outcomes are improving with the availability of increasingly efficacious treatments; however, treatment rates for advanced disease remain low. In this review, we discuss how person-centred outcomes could be improved, how outcomes can be prognosticated and how the 'host' can be staged as well as the cancer. Recent data suggests that early comprehensive supportive care improves quality of life, reduces time spent in hospital and may affect survival.Summary: Comprehensive supportive care is likely to improve quality of life in patients with advanced lung cancer. Further work is needed to see if it can improve treatment rates and survival.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EDA2R-NIK signaling in cancer cachexia. 癌症恶病质中的 EDA2R-NIK 信号转导

IF 1.9 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.1097/SPC.0000000000000705

Samet Agca, Serkan Kir

{"title":"EDA2R-NIK signaling in cancer cachexia.","authors":"Samet Agca, Serkan Kir","doi":"10.1097/SPC.0000000000000705","DOIUrl":"10.1097/SPC.0000000000000705","url":null,"abstract":"Purpose of review: Cachexia is a debilitating condition causing weight loss and skeletal muscle wasting that negatively influences treatment and survival of cancer patients. The objective of this review is to describe recent discoveries on the role of a novel signaling pathway involving ectodysplasin A2 receptor (EDA2R) and nuclear factor κB (NFκB)-inducing kinase (NIK) in muscle atrophy.Recent findings: Studies identified tumor-induced upregulation of EDA2R expression in muscle tissues in pre-clinical cachexia models and patients with various cancers. Activation of EDA2R by its ligand promoted atrophy in cultured myotubes and muscle tissue, which depended on NIK activity. The non-canonical NFκB pathway via NIK also stimulated muscle atrophy. Mice lacking EDA2R or NIK were protected from muscle loss due to tumors. Tumor-induced cytokine oncostatin M (OSM) upregulated EDA2R expression in muscles whereas OSM receptor-deficient mice were resistant to muscle wasting.Summary: Recent discoveries revealed a mechanism involving EDA2R-NIK signaling and OSM that drives cancer-associated muscle loss, opening up new directions for designing anti-cachexia treatments. The therapeutic potential of targeting this mechanism to prevent muscle loss should be further investigated. Future research should also explore broader implications of the EDA2R-NIK pathway in other muscle wasting diseases and overall muscle health.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validity of dietary intake methods in cancer cachexia. 癌症恶病质中膳食摄入方法的有效性。

IF 1.9 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1097/SPC.0000000000000709

Trude R Balstad, Marianne Bråtveit, Tora S Solheim, Lisa Heide Koteng, Asta Bye, Rasmus Dahl Jakobsen, Bente Schødt-Osmo, Siv Hilde Fjeldstad, Marianne Erichsen, Ola Magne Vagnildhaug, Ingvild Paur, Inger Ottestad

{"title":"Validity of dietary intake methods in cancer cachexia.","authors":"Trude R Balstad, Marianne Bråtveit, Tora S Solheim, Lisa Heide Koteng, Asta Bye, Rasmus Dahl Jakobsen, Bente Schødt-Osmo, Siv Hilde Fjeldstad, Marianne Erichsen, Ola Magne Vagnildhaug, Ingvild Paur, Inger Ottestad","doi":"10.1097/SPC.0000000000000709","DOIUrl":"10.1097/SPC.0000000000000709","url":null,"abstract":"Purpose of review: Accurate assessment of dietary intake, especially energy and protein intake, is crucial for optimizing nutritional care and outcomes in patients with cancer. Validation of dietary assessment methods is necessary to ensure accuracy, but the validity of these methods in patients with cancer, and especially in those with cancer cachexia, is uncertain. Validating nutritional intake is complex because of the variety of dietary methods, lack of a gold standard method, and diverse validation measures. Here, we review the literature on validations of dietary intake methods in patients with cancer, including those with cachexia, and highlight the gap between current validation efforts and the need for accurate dietary assessment methods in this population.Recent findings: We analyzed eight studies involving 1479 patients with cancer to evaluate the accuracy and reliability of 24-hour recalls, food records, and food frequency questionnaires in estimating energy and protein intake. We discuss validation methods, including comparison with biomarkers, indirect calorimetry, and relative validation of dietary intake methods.Summary: Few have validated dietary intake methods against objective markers in patients with cancer. While food records and 24-hour recalls show potential accuracy for energy and protein intake, this may be compromised in hypermetabolic patients. Additionally, under- and overreporting of intake may be less frequent, and the reliability of urinary nitrogen as a protein intake marker in patients with cachexia needs further investigation. Accurate dietary assessment is important for enhancing nutritional care outcomes in cachexia trials, requiring validation at multiple time points throughout the cancer trajectory.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141564884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digital clinics for diagnosing and treating migraine. 诊断和治疗偏头痛的数字诊所。

IF 1.9 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-09-01 Epub Date: 2024-07-11 DOI: 10.1097/SPC.0000000000000715

Johan Nyberg, Rikard Rosenbacke, Elinor Ben-Menachem

引用次数: 0

Mechanistic insights into behavioral clusters associated with cancer-related systemic inflammatory response. 洞察与癌症相关的全身炎症反应行为集群的机制。

IF 1.9 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.1097/SPC.0000000000000706

Taichi Goto, Leorey N Saligan

{"title":"Mechanistic insights into behavioral clusters associated with cancer-related systemic inflammatory response.","authors":"Taichi Goto, Leorey N Saligan","doi":"10.1097/SPC.0000000000000706","DOIUrl":"10.1097/SPC.0000000000000706","url":null,"abstract":"Purpose of review: This focused, narrative review mostly describes our team's investigations into the potential inflammatory mechanisms that contribute to the development of cancer-related gastrointestinal (GI) mucositis and its associated symptoms. This review summarizes details of our clinical and preclinical findings to test the role of inflammation in the development and occurrence of these cancer-related conditions.Recent findings: GI mucositis (GIM) is a common, distressing condition reported by cancer patients. GIM is often clustered with other behaviors including fatigue, pain, anorexia, depression, and diarrhea. It is hypothesized that there is a common biologic mechanism underpinning this symptom cluster. Our multi-platform investigations revealed that GIM and its associated cluster of behaviors may be triggered by local inflammation spreading systemically causing pro-inflammatory-mediated toxicities, leading to alterations in immune, metabolic, and nervous system functions and activities. For example, behavioral toxicities related to local irradiation for non-metastatic cancer may be triggered by mGluR5 activation influencing prolonged T cell as well as NF-κB transcription factor activities. Thus, interventions targeting inflammation and associated pathways may be a reasonable strategy to alleviate GIM and its symptom cluster.Summary: GIM may be a sign of a broader systemic inflammatory response triggered by cancer or its treatment. Addressing GIM and its associated symptoms primarily involves supportive care strategies focused on relieving symptoms, promoting healing, and preventing complications.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mirogabalin: a novel gabapentinoid or another false dawn? 米罗加巴林：新型加巴喷丁类药物还是另一个假曙光？

IF 1.9 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1097/SPC.0000000000000714

Thomas J Craig, Paul Farquhar-Smith

{"title":"Mirogabalin: a novel gabapentinoid or another false dawn?","authors":"Thomas J Craig, Paul Farquhar-Smith","doi":"10.1097/SPC.0000000000000714","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000714","url":null,"abstract":"Purpose of review: Mirogabalin is a novel gabapentinoid medication for the treatment of neuropathic pain. The purpose of this review is to discuss current evidence for its use. Gabapentinoids are widely prescribed for neuropathic pain. Mirogabalin offers theoretical advantages over traditional gabapentinoids due to its specificity for the α2δ-1 subunit of voltage-gated calcium channels. It is theorised that this specificity may reduce adverse drug reactions by minimising binding to the α2δ-2 subunit which is responsible for many of the gabapentinoid side effects.Recent findings: Mirogabalin's slower dissociation from the α2δ-1 compared with α2δ-2, and its higher potency may also impart an efficacy benefit over traditional gabapentinoids. These theoretical advantages of mirogabalin remain inconclusive in clinical practice, with mixed evidence regarding mirogabalin versus traditional gabapentinoids. Some studies suggest a reduced side effect profile yet, others fail to demonstrate significant differences. Regarding efficacy, mirogabalin may be superior to placebo for several neuropathic pain syndromes, but evidence of widespread benefit over traditional gabapentinoids is currently lacking.Summary: Mirogabalin offers theoretical promise, but large, independent studies are required to further assess its performance versus traditional gabapentinoids.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In support of rigor and reproducibility in cancer cachexia research. 支持癌症恶病质研究的严谨性和可重复性。

IF 1.9 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1097/SPC.0000000000000708

Aminah Jatoi, Barry Laird

引用次数: 0

The systemic outcomes of gastrointestinal mucositis: host-microbe interaction leading to systemic inflammatory responses. 胃肠道粘膜炎的全身后果：宿主与微生物相互作用导致全身炎症反应。

IF 2.1 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-06-01 Epub Date: 2024-04-30 DOI: 10.1097/SPC.0000000000000704

Andrea Stringer

引用次数: 0

Supportive care measures for bispecific T-cell engager therapies in haematological malignancies. 血液恶性肿瘤双特异性 T 细胞捕获疗法的支持性护理措施。

IF 2.1 4区医学

Current Opinion in Supportive and Palliative Care Pub Date : 2024-04-23 DOI: 10.1097/SPC.0000000000000699

Lucia Y Chen, J. Kothari

{"title":"Supportive care measures for bispecific T-cell engager therapies in haematological malignancies.","authors":"Lucia Y Chen, J. Kothari","doi":"10.1097/SPC.0000000000000699","DOIUrl":"https://doi.org/10.1097/SPC.0000000000000699","url":null,"abstract":"PURPOSE OF REVIEW\u0000Bispecific T-cell engager (TCE) therapies are revolutionizing the treatment of several haematological malignancies, including B-cell acute lymphoblastic leukaemia, various subtypes of B-cell non-Hodgkin lymphoma, and multiple myeloma. Due to their unique mode of action in activating endogenous T cells, they are associated with several important early side effects, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as target-specific toxicities and a significant risk of infection.\u0000\u0000\u0000RECENT FINDINGS\u0000Currently, supportive care measures for TCEs have largely been inferred from other T-cell therapies, such as CAR-T (chimeric antigen receptor) therapy. Further research into TCE-specific supportive care measures is needed to improve the tolerability of these therapies for patients. A key question moving forward is understanding how to predict and minimize early toxicity (cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome). Associated infection risk is a significant cause of patient morbidity, therefore a better understanding of how to optimize TCE-dosing and prophylactic measures, such as intravenous immunoglobulin and antimicrobials, will be crucial to achieving an improved balance of toxicity and efficacy. Enabling early outpatient delivery of these therapies to select patients at lower risk of toxicity may also help to improve patient experience and quality of life.\u0000\u0000\u0000SUMMARY\u0000Here we review up-to-date guidance and literature on existing supportive care measures for bispecific TCE therapy-related toxicities. We highlight both unique and serious side effects of TCE therapies that require improved management strategies to enable more patients to benefit from these efficacious drugs.","PeriodicalId":48837,"journal":{"name":"Current Opinion in Supportive and Palliative Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140666346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0